In vitro activity of apramycin against 16S-RMTase-producing Gram-negative isolates - Université Paris Cité Accéder directement au contenu
Article Dans Une Revue Journal of Global Antimicrobial Resistance Année : 2023

In vitro activity of apramycin against 16S-RMTase-producing Gram-negative isolates

Résumé

Objectives: Apramycin is an aminoglycoside (AG) with a unique structure that is little affected by plasmid-mediated mechanisms of AG resistance, including most AG-modifying enzymes and 16S rRNA methyltransferases (16S-RMTases). We evaluate the activity of apramycin against a collection of 16S-RMTase-producing isolates, including Enterobacterales, non-fermenting bacteria, and carbapenemase producers. Methods: In total, 164 non-duplicate 16S-RMTase-producing isolates, including 84 Enterobacterales, 53 Acinetobacter baumannii and 27 Pseudomonas aeruginosa isolates, were included in the study. Wholegenome sequencing (WGS) was performed on all isolates with Illumina technology. The minimum inhibitory concentration (MIC) of apramycin was determined by broth microdilution with customized Sensititre plates (Thermo Fisher Scientific, Dardilly, France). Results: We found that 95% (156/164) of the 16S-RMTase-producing isolates were susceptible to apramycin, with a MIC 50 of 4 mg/L and a MIC 90 of 16 mg/L, respectively. Resistance rates were higher in P. aeruginosa (11%) than in A. baumannii (4%) or Enterobacterales (4%) (P < 0.0 0 01 for each comparison). Eight isolates were resistant to apramycin, including one isolate with an MIC > 64 mg/L due to the acquisition of the aac(3)-IV gene. The genetic environment of the aac(3)-IV gene was similar to that in the pAH01-4 plasmid of an Escherichia coli isolate from chicken in China. Conclusion: Resistance to apramycin remains rare in 16S-RMTase-producing isolates. Apramycin may, therefore, be an interesting alternative treatment for infections caused by 16S-RMTase and carbapenemase producers.
Fichier principal
Vignette du fichier
apramycin.pdf (483.25 Ko) Télécharger le fichier
Origine Fichiers éditeurs autorisés sur une archive ouverte
Licence

Dates et versions

hal-04088355 , version 1 (04-05-2023)

Licence

Identifiants

Citer

François Caméléna, Mathilde Liberge, Inès Rezzoug, Manel Merimèche, Thierry Naas, et al.. In vitro activity of apramycin against 16S-RMTase-producing Gram-negative isolates. Journal of Global Antimicrobial Resistance, 2023, 33, pp.21-25. ⟨10.1016/j.jgar.2023.02.005⟩. ⟨hal-04088355⟩
7 Consultations
26 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More